Form 4: Aspira Women's Health Director Plans Option Acquisition

Aspira Women's Health Inc. Director Jeffrey K. Cohen has pre-scheduled the acquisition of 213,518 stock options with an exercise price of $0.35, effective December 2, 2025, under a Rule 10b5-1 plan.

Summary

• Jeffrey K. Cohen, a Director of Aspira Women's Health Inc. (AWHL), is scheduled to acquire 213,518 derivative securities in the form of stock options.
• The transaction is set to occur on December 2, 2025, and was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary transaction.
• Each stock option grants the right to buy one share of Common Stock at an exercise price of $0.35.
• The options will become exercisable on December 2, 2025, and will expire on December 2, 2035.
• Following this acquisition, Mr. Cohen will beneficially own 213,518 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a routine, pre-scheduled grant of stock options to a director, which is a positive for aligning management incentives with shareholder interests. It does not contain any negative or unexpected information.

Positives

• The acquisition of stock options by a director aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• The use of a Rule 10b5-1 plan for the transaction enhances transparency and provides an affirmative defense against potential insider trading allegations, demonstrating good corporate governance.

Risks

• No specific risks are detailed in this transactional filing, which primarily reports an insider's equity compensation.

Future Outlook

The filing indicates a pre-scheduled acquisition of stock options by Director Jeffrey K. Cohen on December 2, 2025, under a Rule 10b5-1 plan. These options, exercisable at $0.35, have a ten-year term, suggesting a long-term incentive for the director to align with shareholder value creation and the company's future performance.

Industry Context

The grant of stock options to directors is a common practice across industries, particularly in publicly traded companies, to attract, retain, and incentivize leadership. It aligns the interests of the director with the long-term success and share price appreciation of the company.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice, comparable to equity incentive programs seen in many public companies, especially those in the healthcare or biotechnology sectors.
• The use of a Rule 10b5-1 plan for pre-scheduled transactions is a widely adopted best practice in corporate governance, similar to plans implemented by executives and directors at companies like Pfizer or Johnson & Johnson to manage insider trading compliance.

Corporate Governance

Related Party Transactions

• Director Jeffrey K. Cohen is scheduled to acquire 213,518 stock options from Aspira Women's Health Inc. as part of his compensation, which is a standard insider transaction.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will become exercisable on December 2, 2025.
• The director may choose to exercise these options at any point between the exercisable date and the expiration date (December 2, 2035).

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled grant of stock options to a director as part of their compensation, which is a standard practice for aligning interests. It does not provide new information that would significantly alter the investment thesis for Aspira Women's Health Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Aspira Women's Health, AWHL, Jeffrey Cohen, Stock Options, Director, Insider Transaction, Form 4, Equity Compensation, Rule 10b5-1